The pre-seed round was funded by Keio Innovation Initiative, Inc. and backed CLOVERNA’s first raise. CLOVERNA is a revolutionary RNA target drug discovery technology to accelerate the rare disease treatment pipeline. The funds will be used to move their collaborative research and development projects for RNA therapeutics forward.
CLOVERNA, the Okayama, Japan-based, first Kawasaki Medical School-led startup company working with biotechnology to develop RNA therapeutic drugs, ann ...
Satisfied Users & 
Approved Press Releases
